Comparative Pharmacology
Head-to-head clinical analysis: EMCYT versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMCYT versus TREANDA.
EMCYT vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estramustine is a combination of estradiol and nitrogen mustard. The estradiol moiety targets the drug to cells expressing estrogen receptors, while the nitrogen mustard alkylates DNA, inhibiting cell division primarily in prostate cancer cells.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
Estramustine phosphate sodium: 14 mg/kg/day orally in 3-4 divided doses, typically 140 mg four times daily. Administer on an empty stomach (1 hour before or 2 hours after meals).
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Terminal half-life of estramustine phosphate: ~20 hours; estromustine: ~14 hours; clinical context: supports daily dosing with accumulation over 5-7 days
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal: primarily as estramustine phosphate, estromustine, and estradiol; <1% as unchanged drug; fecal: ~15%
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category C
Category C
Alkylating Agent
Alkylating Agent